PD-1 blockade in renal cell carcinoma: to equilibrium and beyond.
作者： Lauren C. Harshman , Charles G. Drake , Toni K. Choueiri
DOI: 10.1158/2326-6066.CIR-14-0193
关键词:
摘要: … -L1–PD-1, class II MHC/LAG-3, Galectin-9/Tim-3, and VEGF. Having escaped the immune system's defense mechanisms, these tumors proliferate and are the ones we face in the clinic. …
aacrjournals.org
elsevier.com
sci-hub.se 参考文章(59)
Asim Amin, Elizabeth R. Plimack, Jeffrey R. Infante, Marc S. Ernstoff, Brian I. Rini, David F. McDermott, Jennifer J. Knox, Sumanta Kumar Pal, Martin Henner Voss, Padmanee Sharma, Christian K. Kollmannsberger, Daniel Yick Chin Heng, Jennifer L. Spratlin, Yun Shen, John F. Kurland, Paul Gagnier, Hans J. Hammers, Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. ,vol. 32, pp. 5010- 5010 ,(2014) , 10.1200/JCO.2014.32.15_SUPPL.5010
Leisha A. Emens, Richa Gupta, GM-CSF-secreting vaccines for solid tumors: moving forward. Discovery Medicine. ,vol. 10, pp. 52- 60 ,(2010)
Guru Sonpavde, Toni K. Choueiri, Precision medicine for metastatic renal cell carcinoma11Disclosures: Guru Sonpavde, MD: Research support from Novartis, Pfizer, and speaker or advisory board for Novartis, Pfizer, and GSK. Toni K. Choueiri, MD: Research support from Pfizer. Advisory board: Pfizer, Novartis, Aveo, GSK, Bayer/Onyx, and Genentech. No speakers bureau. Urologic Oncology: Seminars and Original Investigations. ,vol. 32, pp. 5- 15 ,(2014) , 10.1016/J.UROLONC.2013.07.010
Robert J. Motzer, Brian I. Rini, David F. McDermott, Bruce G. Redman, Timothy Kuzel, Michael Roger Harrison, Ulka N. Vaishampayan, Harry A. Drabkin, Saby George, Theodore F. Logan, Kim Allyson Margolin, Elizabeth R. Plimack, Ian Waxman, Alexandre Lambert, Hans J. Hammers, Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial. Journal of Clinical Oncology. ,vol. 32, pp. 5009- 5009 ,(2014) , 10.1200/JCO.2014.32.15_SUPPL.5009
Daniel C Cho, Jeffrey Alan Sosman, Mario Sznol, Michael S Gordon, Antoine Hollebecque, Omid Hamid, David F McDermott, Jean-Pierre Delord, Ina Park Rhee, Ahmad Mokatrin, Marcin Kowanetz, Roel Peter Funke, Gregg Daniel Fine, Thomas Powles, None, Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. ,vol. 31, pp. 4505- 4505 ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.4505
W. Scott Webster, Christine M. Lohse, R. Houston Thompson, Haidong Dong, Xavier Frigola, Demetrius L. Dicks, Shomik Sengupta, Igor Frank, Bradley C. Leibovich, Michael L. Blute, John C. Cheville, Eugene D. Kwon, Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival Cancer. ,vol. 107, pp. 46- 53 ,(2006) , 10.1002/CNCR.21951
Arianna Di Napoli, Sabina Signoretti, Tissue biomarkers in renal cell carcinoma: issues and solutions. Cancer. ,vol. 115, pp. 2290- 2297 ,(2009) , 10.1002/CNCR.24233
E J Bromwich, P A McArdle, K Canna, D C McMillan, A-M McNicol, M Brown, M Aitchison, The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. British Journal of Cancer. ,vol. 89, pp. 1906- 1908 ,(2003) , 10.1038/SJ.BJC.6601400
Christopher R Parish, Cancer immunotherapy: the past, the present and the future. Immunology and Cell Biology. ,vol. 81, pp. 106- 113 ,(2003) , 10.1046/J.0818-9641.2003.01151.X
R. D. Schreiber, L. J. Old, M. J. Smyth, Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion Science. ,vol. 331, pp. 1565- 1570 ,(2011) , 10.1126/SCIENCE.1203486